Correlated Drug Terms (0)

---

	Name (Synonyms)	Correlation

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D019851	Thrombophilia NIH	0.58

Correlated HPO Terms (1)

---

	Name (Synonyms)	Correlation
HP:0100724	Hypercoagulability HPO	0.58

Primary Outcomes

Description: Systemic levels of IL-6, IL-8 and TNF-α are evaluated to assess the effect of blood purification. Measurement points: at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in cytokine levels of Interleukin (IL) 6, IL-8 and Tumor Necrosis Factor-α (pg/mL)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

Description: Systemic levels of proinflammatory mediators are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

Measure: Changes in inflammatory markers; C-Reactive Protein (CRP) (mg/L)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

Description: Systemic levels of thrombocytes are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

Measure: Changes in thrombocyte counts (10^3 counts/microL)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in the coagulation marker Fibrinogen (g/L)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

Description: Duration of intensive care will be determined in relation to the number of blood purification cycles Patients will be followed for the duration of ICU stay.

Measure: ICU length of stay after admission (days)

Time: An expected average of 4 - 14 hospitalisation days or until hospital discharge (whichever comes first)

---

Secondary Outcomes

Description: Systemic levels of proinflammatory mediators are measured as a marker for disease severity. Measurement points: at admission, "before and after a blood purification cycle" and before discharge.

Measure: Changes in Neutrophil-to-Lymphocyte Ratio

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in the coagulation marker D-Dimers (ng/mL)

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

Description: Coagulation markers will be followed to assess the effect of systemic heparinisation, Measurement points, at admission, "before and after a blood purification cycle" and before discharge

Measure: Changes in the Activation Clotting Time (seconds).

Time: Hospitalisation window, day 0 until day 14 or until hospital discharge (whichever comes first)

---

HP:0100724: Hypercoagulability

Genes 20

SLC4A1 SPTA1 F9 DLD AGGF1 MYD88 SPTB ANK1 PROS1 PLAT PROC EPB42 PROC GATA2 THBD F5 HBB PIGA HRG PROS1

Protein Mutations 2

G20210A V617F

SNP 2

rs1799963 rs6025